News | Stents | August 21, 2019

Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025

New drug discoveries, continued research into bioresorbable stents expected to drive market growth

Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025

August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the global cardiovascular stents market, predicts Fortune Business Insights in a new study.

The study is titled, “Cardiovascular Stents Market: Global Market Analysis, Insights and Forecasts, 2018 – 2025”. As per Fortune Business Insights, the market is prognosticated to exhibit a 6.6 percent compound annual growth rate (CAGR).

In terms of stent type, the drug-eluting stents (DES) segment is expected to hold the dominant position in the market. This dominance is attributable to key companies introducing next-generation drugs for DES, and is likely to continue in the coming years. 

With respect to end users, the hospitals segment holds dominance in the global market as it registers the highest consumption of cardiovascular stents.

The global market derives growth from a number of factors such as increasing focus on research and development (R&D). Besides this, increasing regulatory approvals from organizations such as the U.S. Food and Drug Administration (FDA) have contributed significantly to the global cardiovascular stents market.  

Furthermore, newer drug discoveries as a result of emphasis on R&D have favored the growth of the global cardiovascular stents market and are likely to boost the market in the coming years, backed by contributions from government as well as private organizations. 

In 2017, coronary stenting procedures were the most common treatment among cardiovascular patients, with a market share of 66.9 percent. The rising number of cardiovascular diseases worldwide is expected to drive the global market, as per analysts at Fortune Business Insights.

Besides this, huge investments made by market players in research and development on environmental and bioresorbable coronary stents is also anticipated to boost the market. 

Generally unhealthy lifestyles and irregular eating habits have led to an increase in the prevalence of health-related concerns, including chronic diseases such as diabetes, obesity and heart disorders. The surging cases of heart disorder is continuously fueling the demand for new cardiovascular treatments including angioplasty, which will ultimately increase the demand for cardiovascular stents, according to the report.

However, the market may face challenges due to the presence of alternative treatment methods for vascular diseases. The complexity of cardiovascular stent implantation may cause patients to opt for other treatment options and this may restrict growth in the market. Besides this, high-profile incidents of product recalls and failures may also hamper the market in future, according to Fortune Business Insights. Nevertheless, the emerging market for cardiovascular stents and their rapid ascent is likely to boost growth opportunities for the market in the long run. 

The North American market has emerged as the dominant market segment worldwide as of 2017. This is mainly due to the presence of better medical facilities and skilled professionals in the developed nations of Canada and the U.S, according to the report. North America is likely to remain dominant in the coming years as well, on account of ongoing clinical trials on novel stents in the U.S. and various regulatory approvals for cardiovascular stents. 

At the same time, the Asia Pacific is projected to show the most growth during the report period on account of improved distribution of cardiovascular stents in emerging economies such as China and India. In order to improve their accessibility, price capping of stents has been introduced in these developing nations and this will help the market gain momentum.

You can read the full report here.

For more information: www.fortunebusinessinsights.com

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021